IQVIA Holdings Inc. IQV | NYSE
Next Earnings: May 06, 2025
Company Overview:
10 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
IQV Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for IQV
Based on past 10-year performance, here are IQV growth metrics:
Share price CAGR of +8.42%
Dividend CAGR of +0%
Using IQV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| IQV (DRIP) | IQV - No DRIP | |
|---|---|---|
| Current Price | $151.10 | $151.10 |
| Start Shares | 66.18 | 66.18 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 66.18 | 66.18 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $312.89 | $151.10 |
| Total Dividends | $0 | $0 |
| Final Value | $20,707 | $10,000 |
NOTE: Above numbers are our estimate based on IQV's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
IQVIA Holdings Inc. (IQV) had its IPO on 2013-05-09, and is trader on NYSE stock exchange.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQV website: https://www.iqvia.com
